BioRestorative Therapies (NASDAQ:BRTX) Shares Up 1.3%

Posted by Defense World Staff on Sep 7th, 2024

BioRestorative Therapies, Inc. (NASDAQ:BRTX – Get Free Report)’s share price was up 1.3% during trading on Friday . The company traded as high as $1.57 and last traded at $1.53. Approximately 5,443 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 979,865 shares. The stock had previously closed at $1.51.

Wall Street Analyst Weigh In

Separately, Roth Mkm upped their price target on BioRestorative Therapies from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th.

Check Out Our Latest Analysis on BRTX

BioRestorative Therapies Stock Performance

The business has a fifty day moving average of $1.65 and a 200-day moving average of $1.50. The company has a market capitalization of $10.36 million, a P/E ratio of -0.66 and a beta of 63.07.

BioRestorative Therapies (NASDAQ:BRTX – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.06. The firm had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.03 million. BioRestorative Therapies had a negative net margin of 6,898.28% and a negative return on equity of 107.65%. During the same period last year, the firm earned ($0.77) earnings per share. Sell-side analysts anticipate that BioRestorative Therapies, Inc. will post -1.83 EPS for the current year.

Hedge Funds Weigh In On BioRestorative Therapies

A hedge fund recently bought a new stake in BioRestorative Therapies stock. StoneX Group Inc. bought a new stake in BioRestorative Therapies, Inc. (NASDAQ:BRTX – Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 34,850 shares of the company’s stock, valued at approximately $48,000. StoneX Group Inc. owned approximately 0.51% of BioRestorative Therapies as of its most recent SEC filing. 69.38% of the stock is owned by institutional investors.

About BioRestorative Therapies

(Get Free Report)

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.